SEARCH

SEARCH BY CITATION

REFERENCES

  • Bargmann CI. 1998. Neurobiology of the Caenorhabditis elegans genome. Science 282: 20282033.
  • Bembi B, Ciana G, Martini C, Benettoni A, Gombacci A, Deganuto M, Pittis MG. 2003. Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II. J Inherit Metab Dis 26: 675681.
  • Bilen J, Bonini NM. 2005. Drosophila as a model for human neurodegenerative disease. Ann Rev Genet 39: 153171.
  • Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. 2004. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screening. Neurodegener Dis 1: 175183.
  • C. elegans Sequencing Consortium. 1998. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282: 20122018.
  • Caldwell GA, Caldwell KA. 2008. Traversing a wormhole to combat Parkinson's disease. Dis Model Mech 1: 3236.
  • Caldwell KA, Tucci ML, Armagost J, Hodges TW, Chen J, Memon SB, Blalock JE, DeLeon SM, Findlay RH, Ruan Q, Webber PJ, Standaert DG, Olson JB, Caldwell GA. 2009. Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PLoS One 4: e7227.
  • Cao S, Gelwix CC, Caldwell KA, Caldwell GA. 2005. Torsin-mediated neuroprotection from cellular stresses to dopaminergic neurons of C. elegans. J Neurosci 25: 38013812.
  • Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, Chen P, Nery FC, Li Y, Breakefield XO, Caldwell GA, Caldwell KA. 2010. Chemical enhancement of torsinA function in cell and animal models of torsin dystonia. Dis Model Mech (in press).
  • Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. 1994. Green fluorescent protein as a marker for gene expression. Science 263: 802805.
  • Clayton DF, George JM. 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21: 249254.
  • Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571576.
  • Conway KA, Rochet JC, Bieganski RM, Lansbury PT. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 13461349.
  • Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S. 2006. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324328.
  • Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. 2004. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 12921295.
  • Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39: 889909.
  • Dawson TM, Dawson VL. 2003. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111: 145151.
  • Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. 2008. Mitochondrial import and accumulation of alpha-synuclein impair complex 1 in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 90899100.
  • Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V. 2005. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365: 412415.
  • Fahn S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991: 114.
  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806811.
  • Fleming SM, Chesselet MF. 2006. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol 17: 383391.
  • Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, Britton A, Bibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, Rodríguez RL, Peckham E, De Vrieze FW, Gwinn-Hardy K, Hardy JA, Singleton A. 2006. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet 5: 911916.
  • Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. 2005. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415416.
  • Gitler AD. 2008. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 16: 5262.
  • Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S. 2008. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105: 145150.
  • Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. 2009. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41: 308315.
  • Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. 2008. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci U S A 105: 728733.
  • Hasegawa T, Treis A, Patenge N, Fiesel FC, Springer W, Kahle PJ. 2008. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathway. J Neurochem 105: 17001715.
  • Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105: 891902.
  • Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R. 2002. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 10: 5567.
  • Iwata A, Maruyama M, Kanazawa I, Nukina N. 2001. Alpha-synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276: 4532045329.
  • Jiang H, Ren Y, Zhao J, Feng J. 2004. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13: 17451754.
  • Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. 2005. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A 102: 96919696.
  • Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. 2009. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 106: 1305213057.
  • Kamath RS, Ahringer J. 2003. Genome-wide RNAi screening in Caenorhabditis elegans. Methods 30: 313321.
  • Karpinar DP, Balija MB, Kügler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jäckle H, Eimer S, Schulz JB, Griesinger C, Zweckstetter M. 2009. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 28: 32563268.
  • Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. 2007. A microRNA feedback circuit in midbrain dopamine neurons. Science 317: 12201224.
  • Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. 2006. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 444: 880884.
  • Kuwahara T, Koyama A, Gengyo-Ando K, Masuda M, Kowa H, Tsunoda M, Mitani S, Iwatsubo T. 2006. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfucntion in transgenic Caenorhabditis elegans. J Biol Chem 281: 334340.
  • Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren CH, Kato T, Mitani S, Iwatsubo T. 2008. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum Mol Genet 17: 29973009.
  • Lakso M, Vartiainen S, Moilanen AM, Sirviö J, Thomas JH, Nass R, Blakely RD, Wong G. 2003. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165172.
  • Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979980.
  • Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. 2002. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322: 10891102.
  • Lee JC, Langen R, Hummel PA, Gray HB, Winkler JR. 2004. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease. Proc Natl Acad Sci U S A 101: 1646616471.
  • Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373: 20552066.
  • Lotharius J, Brundin P. 2002. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932942.
  • Maranova M, Nichols CD. 2007. Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31: 127137.
  • McDonald PW, Jessen T, Field JR, Blakely RD. 2006. Dopamine signaling architecture in Caenorhabditis elegans. Cell Mol Neurobiol 26: 593618.
  • Mezey E, Dehejia AM, Harta G, Tresser N, Suchy SF, Nussbaum RL, Brownstein MJ, Polymeropoulos MH. 1998. Alpha-synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 2: 493499.
  • Moss EG, Poethig RS. 2002. MicroRNAs: something new under the sun. Curr Biol 12: R688R690.
  • Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Hao L, Kenyon C. 2003. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424: 277283.
  • Nass R, Hall DH, Miller DM III, Blakely RD. 2002. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci U S A 99: 32643269.
  • Nass R, Hahn MK, Jessen T, McDonald PW, Carvelli L, Blakely RD. 2005. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitive to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J Neurochem 94: 774785.
  • Nonaka T, Hasegawa M. 2009. A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry 48: 80148022.
  • Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5: e172.
  • Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. 2001. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86: 122127.
  • Qiao L, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S, Xie ZL, Speake LD, Parks R, Crabtree D, Liang Q, Crimmins S, Schneider L, Uchiyama Y, Iwatsubo T, Zhou Y, Peng L, Lu Y, Standaert DG, Walls KC, Shacka JJ, Roth KA, Zhang J. 2008. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 1: 17.
  • Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C, et al. 2006. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 11841191.
  • Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. 2004. Alpha-synuclein and Parkinson's disease. FASEP J 18: 617626.
  • Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. 2008. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63: 743750.
  • Ruan Q, Harrington AJ, Caldwell KA, Caldwell GA, Standaert DG. 2009. VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol Dis [Epub ahead of print].
  • Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B. 2009. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 92109218.
  • Sämann J, Hegermann J, von Gromoff E, Eimer S, Baumeister R, Schmidt E. 2009. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 284: 1648216491.
  • Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, Shimohama S. 2004. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279: 1071010719.
  • Sawin ER, Ranganathan R, Horvitz HR. 2000. C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26: 619631.
  • Sen S, Webber PJ, West AB. 2009. Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 284: 3634636356.
  • Settivari R, LeVora J, Nass R. 2009. The divalent metal transporter homologues SMF-1/2 mediates dopamine neuron sensitivity in Caenorhabditis elegans models of manganism and Parkinson's disease. J Biol Chem 284: 3575835768.
  • Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302305.
  • Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361: 16511661.
  • Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841.
  • Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, Sawa A, Dawson VL, Dawson TM, Ross CA. 2005. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Hum Mol Genet 14: 38013811.
  • Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839840.
  • Springer W, Hoppe T, Schmidt E, Baumeister R. 2005. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet 14: 34073423.
  • Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21: 95499560.
  • Sulston J, Dew M, Brenner S. 1975. Dopaminergic neurons in the nematode C. elegans. J Comp Neurol 163: 215226.
  • Tissenbaum HA, Guarente L. 2001. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227230.
  • Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR. 2004. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56: 336341.
  • van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA. 2008. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet 4: e1000027.
  • Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. 2005. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280: 4265542668.
  • Viswanathan M, Kim SK, Berdichevsky A, Guarente L. 2005. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev Cell 9: 605615.
  • Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr. 2001. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 78127819.
  • Wang HQ, Imai Y, Inoue H, Kataoka A, Iita S, Nukina N, Takahashi R. 2008. Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss. J Neurochem 107: 171185.
  • Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. 2003. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278: 2500925013.
  • Welch K, Yuan J. 2003. Alpha-synuclein oligomerization: a role for lipids? Trends Neurosci 26: 517519.
  • West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 1684216847.
  • West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223232.
  • Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. 2000. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 97: 1335413359.
  • Zhang NY, Tang Z, Liu CW. 2008. Alpha-synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem 283: 2028820298.